We are seeking approximately 76 participants to take part in a 28-day randomized, double-blind, placebo-controlled study comparing three Qualia NAD⁺ formulations on their effects on intracellular NAD⁺ levels in healthy adults aged 35–75 years. Participants will be randomly assigned to one of four study arms. Each participant will take 2 capsules once daily in the morning, with or without food, for 28 consecutive days.
This is a biomarker study that will require two at-home finger-stick blood collections — one at baseline and one at the end of the study (Day 28). You will be mailed a Revvity® NAD⁺ finger-stick test kit, which you will self-administer at home and return via prepaid mail. All test kits are paid for by Qualia Life Sciences. No in-person visits are required — all participation is fully remote.
The study will also include self-report questionnaires assessing aging-related symptoms, health-related quality of life, and safety and tolerability, completed at baseline, Weeks 1–3, and study completion. A brief follow-up questionnaire will be completed at Day 32.
Upon completion of all study requirements, participants will receive a $300 credit at Qualia Life Sciences as a thank-you for their time and participation. Participants will also receive their personal intracellular NAD⁺ test results at the end of the study.
*US only
*This study is being conducted by Qualia Life Science
Pre-screening surveys are used solely to determine eligibility for participation.
Data will be securely stored on Qualia Life Sciences servers, accessible only to authorized personnel.
A final follow-up survey will be sent to collect additional feedback and reviews that may be featured in our marketing materials.